tirzepatide and not losing weight Loss Plateau: Why Results Vary Semaglutide vs. Tirzepatide for Weight

*Retatrutide is a novel medication that acts on GLP1, GIP, and Glucagon receptors

Participants who received semaglutide had a 24% risk reduction for the composite primary endpoint, including kidney outcomes and death due to cardiovascular and kidney causes, compared to those who received placebo

Each one has been observed in enforcement actions, patient complaints, and investigations by the FDA, state boards of pharmacy, and state attorneys general

If you were thriving on high-dose tirzepatide, switching to semaglutide may require accepting slightly reduced efficacy or exploring peptide stacking strategies to maintain results